Communications publiées lors de congrès ou colloques nationaux et internationaux (22)
21.
Kerger, J., Aamdal, S., Piccart-Gebhart, M., Awada, A., Ravoet, C., de Valeriola, D., Parmentier, N., Gérard, B., Bizzari, J. P., et al. (1992). Phase II trial with hormono-chemotherapy combining high-dose tamoxifen (HD-TAM), cisplatin (DDP) and fotemustine in metastasic malignant melanoma (MMM): Pilot study evaluation. Proceedings of the Annals of Oncology. Vol. 3 (p. 161).22.
Ravoet, C., Piccart-Gebhart, M., Bron, D., Kerger, J., de Valeriola, D., Awada, A., Bleiberg, H., Lips, S., Dewitte, M., Chatelain, C., et al. (1992). A phase I clinical trial of recombinant human interleukine-6 (rhIL-6) in solid tumors. Proceedings of the American Association for Cancer Research. Vol. 33 (p. 232) (1992). Rapports de recherche, comptes rendus, lettres à l'éditeur, working papers (1)
1.
Vereecken, P., Awada, A., Devriendt, D., Laporte, M., Heenen, M., Sales, F., & Cappello, M. (2004). Concerne: Les approches thérapeutiques innovantes dans le mélanome. Revue médicale de Bruxelles, 25(6), 542. Participations à des congrès et colloques internationaux (12)
2.
Ignatiadis, M., Rothé, F., Laes, J.-F., Lambrechts, D., Smeets, D., Vincent, D., Maetens, M. M., Fumagalli, D., Michiels, S., Drisis, S., Moerman, C., Detiffe, J.-P., Larsimont, D., Awada, A., Piccart-Gebhart, M., & Sotiriou, C. (2014). Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analyses in breast cancer. Poster présenté à la conférence San Antonio Breast Cancer Symposium – SABCS (December 11, 2014: San Antonio, Tx, USA).3.
Polastro, L., Aftimos, P., Ameye, L., Vakili, J., Paesmans, M., Van Den Eerenbeemt, J., Buttice, A., Gombos, A., de Valeriola, D., Piccart-Gebhart, M., & Awada, A. (2014). Results of the Belgian expanded acces program of eribulin (E) in the treatment of metastastic breast cancer (MBC) closely mirrors those of the pivotal phase III trial. American Society of Clinical Oncology Abstract session presented at (2014)4.
Deliens, C., Vanderbeeken, M., Georgala, A., Filleul, O., Papadopoulou, B., Deliens, G., De Beer, A., de Valeriola, D., Piccart-Gebhart, M., Awada, A., Praet, J. P., & Dal Lago, L. (2012). Drugs prescribed for elderly oncologic patients hospitalized in the geriatric oncology unit of Institut Jules Bordet: polypharmacy and impact of clinical pharmacist. Poster présenté à la conférence The 12th SIOG International Congress (25-27 October 2012: Manchester).5.
de Azambuja, E., Lemort, M., Rossari, J., Moulin, C., Buttice, A., D'Hondt, V., Lebrun, F., Lalami, Y., Cardoso, F., Sotiriou, C., Gil, T., Devriendt, D., Marinus, W., Paesmans, M., Piccart-Gebhart, M., & Awada, A. (2011). Phase I study of lapatinib (L) and temozolomide (T) combination for the treatment of progressive brain metastases (BM) in HER2-positive metastatic breast cancer patients (Pts) (LAPTEM, LAP 111172). J Clin Oncol: ASCO Annual Meeting Proceedings. Vol. 29, 15 Suppl, Part I (p. 62) Abstract session presented at ASCO Annual meeting 2011(June 2011: Chicago, IL, USA).6.
de Azambuja, E., Lemort, M., Rossari, J., Moulin, C., Buttice, A., D'Agostini, G., D'Hondt, V., Lebrun, F., Lalami, Y., Cardoso, F., Sotiriou, C., Gil, T., De Vriendt, D., Marinus, W., Paesmans, M., Piccart-Gebhart, M., & Awada, A. (2011). Phase I study of lapatinib (L) and temozolomide (T) combination for the treatment of progressive brain metastases (BM) in HER2-positive metastatic breast cancer patients (Pts) (LAPTEM, LAP 111172). Poster présenté à la conférence ASCO Annual Meeting (2011-06: Chicago, USA).7.
Awada, A., Hendlisz, A., Gil, T., Schwartz, B., Bartholomeus, S., de Valeriola, D., Brendel, E., Haase, C. G., & Piccart-Gebhart, M. (2004). A phase I study of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced, solid tumors. Poster présenté à la conférence 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.9.
Piccart-Gebhart, M., Branle, F., de Valeriola, D., Dubuisson, M., Hennebert, P., Gil, T., Forget, F., Thibault, A., Awada, A., et al. (2001). A phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + docetaxel : a promising combination in patients (pts) with solid tumors. Poster présenté à la conférence American Society of Clinical Oncology (2001).